Literature DB >> 12720540

Serum concentrations of activin and follistatin are elevated and run in parallel in patients with septicemia.

Uwe Michel1, Sandra Ebert, David Phillips, Roland Nau.   

Abstract

OBJECTIVE: Activin is a growth and differentiation factor of many cell types, and has recently been implicated in inflammatory processes. Clinical data linking activin and its binding protein, follistatin (FS), are lacking. We measured serum levels of activin and FS in patients diagnosed with septicemia. PATIENTS AND MEASUREMENTS: Eight male and seven female patients of different ages, various forms of septicemia and different clinical outcome were investigated and compared with age- and sex-matched healthy controls. Serum concentrations of FS, activin, C-reactive protein (CRP) and blood leukocyte counts were determined during septicemia.
RESULTS: The median of the maximum activin concentrations of septicemic patients was 3.9-fold higher than in age- and sex-matched healthy control subjects (P<0.01); the median of the maximum FS concentrations was 2.6-fold higher (P<0.01). The highest increase of activin in septicemic patients was approximately 15.8-fold, whereas FS increased by up to 13.2-fold above normal. FS, activin and CRP serum levels generally paralleled each other, but were not correlated with leukocyte counts or clinical outcome.
CONCLUSIONS: Circulatory concentrations of activin and FS are elevated in patients diagnosed with septicemia, consistent with potential roles in the systemic inflammatory response.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12720540     DOI: 10.1530/eje.0.1480559

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  28 in total

1.  Activin A is a critical component of the inflammatory response, and its binding protein, follistatin, reduces mortality in endotoxemia.

Authors:  Kristian L Jones; Ashley Mansell; Shane Patella; Bernadette J Scott; Mark P Hedger; David M de Kretser; David J Phillips
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-02       Impact factor: 11.205

Review 2.  Hepatokines-a novel group of exercise factors.

Authors:  Cora Weigert; Miriam Hoene; Peter Plomgaard
Journal:  Pflugers Arch       Date:  2018-10-18       Impact factor: 3.657

Review 3.  Activins and Inhibins: Roles in Development, Physiology, and Disease.

Authors:  Maria Namwanje; Chester W Brown
Journal:  Cold Spring Harb Perspect Biol       Date:  2016-07-01       Impact factor: 10.005

4.  Activin A Predicts Left Ventricular Remodeling and Mortality in Patients with ST-Elevation Myocardial Infarction.

Authors:  Jeng-Feng Lin; Shun-Yi Hsu; Ming-Sheng Teng; Semon Wu; Chien-An Hsieh; Shih-Jung Jang; Chih-Jen Liu; Hsuan-Li Huang; Yu-Lin Ko
Journal:  Acta Cardiol Sin       Date:  2016-07       Impact factor: 2.672

5.  Circulating follistatin in patients with chronic kidney disease: implications for muscle strength, bone mineral density, inflammation, and survival.

Authors:  Tetsu Miyamoto; Juan Jesús Carrero; Abdul Rashid Qureshi; Björn Anderstam; Olof Heimbürger; Peter Bárány; Bengt Lindholm; Peter Stenvinkel
Journal:  Clin J Am Soc Nephrol       Date:  2011-02-24       Impact factor: 8.237

6.  Activin A is stimulated by tumor necrosis factor-alpha and modulates collagen gene expression in human amniotic cells.

Authors:  Y Abe; M Komatsubara; M Saito; M Toda; H Shinozaki; T Tamura; Y Kasahara; H Sedakata; T Minegishi
Journal:  J Endocrinol Invest       Date:  2013-02-04       Impact factor: 4.256

Review 7.  The biology of activin: recent advances in structure, regulation and function.

Authors:  Yin Xia; Alan L Schneyer
Journal:  J Endocrinol       Date:  2009-03-09       Impact factor: 4.286

8.  Role of activins and inducible nitric oxide in the pathogenesis of ectopic pregnancy in patients with or without Chlamydia trachomatis infection.

Authors:  Bassem Refaat; Majedah Al-Azemi; Ian Geary; Adrian Eley; William Ledger
Journal:  Clin Vaccine Immunol       Date:  2009-08-19

9.  Upregulation of activin signaling in experimental colitis.

Authors:  You-Qing Zhang; Silvia Resta; Barbara Jung; Kim E Barrett; Nora Sarvetnick
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-07-30       Impact factor: 4.052

10.  Follistatin and Soluble Endoglin Predict 1-Year Nonrelapse Mortality after Allogeneic Hematopoietic Cell Transplantation.

Authors:  Laura F Newell; Todd E DeFor; Corey Cutler; Michael R Verneris; Bruce R Blazar; Jeff S Miller; Joseph H Antin; Alan Howard; Juan Wu; Margaret L MacMillan; Angela Panoskaltsis-Mortari; Daniel J Weisdorf; Shernan G Holtan
Journal:  Biol Blood Marrow Transplant       Date:  2019-11-10       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.